Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) was downgraded by equities researchers at Leerink Swann from an “outperform” rating to a “market perform” rating in a research note issued to investors on Monday, MarketBeat Ratings reports. They presently have a $13.00 price objective on the software maker’s stock, down from their previous price objective of $15.00. Leerink Swann’s target price indicates a potential upside of 4.25% from the stock’s previous close.

MDRX has been the topic of several other research reports. Bank of America Corporation began coverage on shares of Allscripts Healthcare Solutions in a research note on Monday, May 15th. They issued a “neutral” rating and a $14.00 price objective on the stock. Citigroup Inc. upgraded shares of Allscripts Healthcare Solutions from a “hold” rating to a “buy” rating in a report on Friday, March 24th. They noted that the move was a valuation call. Cantor Fitzgerald restated a “neutral” rating and issued a $13.00 target price on shares of Allscripts Healthcare Solutions in a report on Monday, May 15th. BidaskClub upgraded shares of Allscripts Healthcare Solutions from a “strong sell” rating to a “sell” rating in a report on Tuesday, June 13th. Finally, Deutsche Bank AG upgraded shares of Allscripts Healthcare Solutions from a “hold” rating to a “buy” rating and boosted their target price for the company from $12.50 to $14.00 in a report on Friday, March 24th. They noted that the move was a valuation call. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and ten have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $14.59.

Analyst Recommendations for Allscripts Healthcare Solutions (NASDAQ:MDRX)

Allscripts Healthcare Solutions (MDRX) traded down 2.41% on Monday, hitting $12.17. The stock had a trading volume of 2,749,285 shares. The company’s 50 day moving average is $12.03 and its 200-day moving average is $11.73. The firm’s market capitalization is $2.21 billion. Allscripts Healthcare Solutions has a 1-year low of $9.80 and a 1-year high of $15.17.

Allscripts Healthcare Solutions (NASDAQ:MDRX) last issued its quarterly earnings data on Thursday, May 4th. The software maker reported $0.10 earnings per share for the quarter, topping the consensus estimate of $0.09 by $0.01. Allscripts Healthcare Solutions had a negative net margin of 2.93% and a positive return on equity of 5.75%. The company had revenue of $415 million for the quarter, compared to analysts’ expectations of $415.20 million. During the same quarter in the previous year, the firm posted $0.13 earnings per share. Allscripts Healthcare Solutions’s revenue for the quarter was up 20.1% on a year-over-year basis. On average, analysts forecast that Allscripts Healthcare Solutions will post $0.62 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Allscripts Healthcare Solutions, Inc. (MDRX) Lowered to “Market Perform” at Leerink Swann” was posted by American Banking News and is owned by of American Banking News. If you are reading this news story on another site, it was stolen and reposted in violation of US and international copyright and trademark laws. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/06/19/allscripts-healthcare-solutions-inc-mdrx-stock-rating-lowered-by-leerink-swann.html.

In related news, President Richard J. Poulton sold 25,000 shares of the company’s stock in a transaction dated Tuesday, May 16th. The shares were sold at an average price of $12.06, for a total value of $301,500.00. Following the sale, the president now owns 412,488 shares in the company, valued at approximately $4,974,605.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Brian Farley sold 15,000 shares of the company’s stock in a transaction dated Thursday, March 23rd. The stock was sold at an average price of $11.63, for a total transaction of $174,450.00. Following the completion of the sale, the senior vice president now owns 217,861 shares in the company, valued at approximately $2,533,723.43. The disclosure for this sale can be found here. 0.75% of the stock is currently owned by corporate insiders.

Several large investors have recently bought and sold shares of MDRX. Russell Investments Group Ltd. acquired a new stake in Allscripts Healthcare Solutions during the fourth quarter worth $7,178,000. Comerica Bank raised its stake in Allscripts Healthcare Solutions by 5.3% in the fourth quarter. Comerica Bank now owns 138,741 shares of the software maker’s stock worth $1,627,000 after buying an additional 6,945 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in Allscripts Healthcare Solutions by 5.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 6,606,169 shares of the software maker’s stock worth $67,451,000 after buying an additional 343,444 shares in the last quarter. Federated Investors Inc. PA raised its stake in Allscripts Healthcare Solutions by 4.3% in the fourth quarter. Federated Investors Inc. PA now owns 138,906 shares of the software maker’s stock worth $1,418,000 after buying an additional 5,725 shares in the last quarter. Finally, Brown Advisory Inc. acquired a new stake in Allscripts Healthcare Solutions during the fourth quarter worth $342,000.

About Allscripts Healthcare Solutions

Allscripts Healthcare Solutions, Inc (Allscripts) delivers information technology (IT) solutions and services to help healthcare organizations. The Company operates through three segments: Clinical and Financial Solutions, Population Health, and Netsmart. The Clinical and Financial Solutions segment includes the sale of integrated clinical software applications and financial and information solutions.

Receive News & Ratings for Allscripts Healthcare Solutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allscripts Healthcare Solutions Inc. and related companies with MarketBeat.com's FREE daily email newsletter.